Ask AI
Novel Mechanisms and Emerging Treatment Options in mCRPC

CE / CME

New Treatments on the Horizon: Cancer Conversations on Novel Mechanisms and Emerging Treatment Options in mCRPC

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 24, 2025

Expiration: December 23, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

When speaking with a colleague, how would you describe the primary mechanism of action of mevrometostat?

2.

Which of the following patient populations with mCRPC is eligible for enrollment in the ongoing randomized phase III MEVPRO-1 and MEVPRO-2 trials?

3.

Patient Case: A 66-Yr-Old Man With Prostate Cancer



  • A 66-yr-old Black man with a history of localized prostate cancer treated with radical prostatectomy

    • Gleason 4+4, GG 4 prostate adenocarcinoma

    • Positive extracapsular extension and positive right apical margin



  • He developed rising PSA approximately 1 yr after surgery

    • PSA has increased from 0.03 → 0.12 → 0.60 → 1.70 ng/mL over 12 mo

    • PSA doubling time: 3 mo



  • He underwent a bone scan and  CT of chest/abdomen/pelvis that was negative for evidence of recurrent disease; his testosterone level was normal

  • Started on treatment with enzalutamide for nmCRPC in the setting of rapid PSA doubling time


       



  • Again, his PSA started to rise rapidly over 3 mo

  • Standard CT of c/a/p with IV contrast  and PSMA PET scan reveals several retroperitoneal lymph node metastases, but no other sites of disease

  • At this time, he is diagnosed with mCRPC


Which of the following would you recommend as the best next step for this patient?

4.

Patient Case: A 65-Yr-Old Man With mCRPC



  • A 65-yr-old man was diagnosed at age 63 with de novo mHSPC

    • Grade group 4 and PSA 85; CBC/CMP wnl

    • ECOG PS 0



  • PSMA PET revealed 3 axial spine lesions, 1 pelvic bone lesion, retroperitoneal and pelvic lymph node with significant avidity, and no visceral lesions

  • ADT and an ARPI are initiated

    • PSA nadir 0.5

    • Germline/somatic profiling are unremarkable



  • 2 yr later, PSA is 3.5; recent PSMA PET scan is positive in retroperitoneal nodes and same spine lesions (with 1 additional lesion)

Which of the following would you recommend as the best next step for this patient?